These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 32808728)

  • 1. ACTA2-AS1 suppresses lung adenocarcinoma progression via sequestering miR-378a-3p and miR-4428 to elevate SOX7 expression.
    Ying K; Wang L; Long G; Lian C; Chen Z; Lin W
    Cell Biol Int; 2020 Dec; 44(12):2438-2449. PubMed ID: 32808728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression.
    Huang H; Yang C; Zhang Q; Zhuo T; Li X; Li N; Zhu L; Luo C; Gan J; Wu Y
    Bioengineered; 2022 Mar; 13(3):4964-4977. PubMed ID: 35164653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETV4 mediated lncRNA C2CD4D-AS1 overexpression contributes to the malignant phenotype of lung adenocarcinoma cells via miR-3681-3p/NEK2 axis.
    Wang B; Cai Y; Li X; Kong Y; Fu H; Zhou J
    Cell Cycle; 2021 Dec; 20(24):2607-2618. PubMed ID: 34850664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA FBXL19-AS1 induces tumor growth and metastasis by sponging miR-203a-3p in lung adenocarcinoma.
    Wang L; Zhang X; Liu Y; Xu S
    J Cell Physiol; 2020 Apr; 235(4):3612-3625. PubMed ID: 31566718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA ZFPM2-AS1 is involved in lung adenocarcinoma via miR-511-3p/AFF4 pathway.
    Li J; Ge J; Yang Y; Liu B; Zheng M; Shi R
    J Cell Biochem; 2020 Mar; 121(3):2534-2542. PubMed ID: 31692047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA TTN-AS1 drives invasion and migration of lung adenocarcinoma cells via modulation of miR-4677-3p/ZEB1 axis.
    Zhong Y; Wang J; Lv W; Xu J; Mei S; Shan A
    J Cell Biochem; 2019 Oct; 120(10):17131-17141. PubMed ID: 31173403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA TMPO-AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR-383-5p.
    Mu X; Wu H; Liu J; Hu X; Wu H; Chen L; Liu W; Luo S; Zhao Y
    Biomed Pharmacother; 2020 May; 125():109989. PubMed ID: 32062549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5.
    Jia Y; Duan Y; Liu T; Wang X; Lv W; Wang M; Wang J; Liu L
    Cell Death Dis; 2019 Jul; 10(8):573. PubMed ID: 31363080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SGMS1-AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR-106a-5p/MYLI9 axis.
    Liu T; Yang C; Wang W; Liu C
    Thorac Cancer; 2021 Jul; 12(14):2104-2112. PubMed ID: 34061466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14.
    Xiao G; Wang P; Zheng X; Liu D; Sun X
    Cell Cycle; 2019 Nov; 18(21):2972-2985. PubMed ID: 31522616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA OIP5-AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR-378a-3p.
    Wang M; Sun X; Yang Y; Jiao W
    Thorac Cancer; 2018 Aug; 9(8):939-949. PubMed ID: 29897167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness
    Guo H; Li T; Peng C; Mao Q; Shen B; Shi M; Lu H; Xiao T; Yang A; Liu Y
    Hum Exp Toxicol; 2022; 41():9603271221138971. PubMed ID: 36461613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA LOXL1-AS1 regulates the tumorigenesis and development of lung adenocarcinoma through sponging miR-423-5p and targeting MYBL2.
    Li W; Zhang B; Jia Y; Shi H; Wang H; Guo Q; Li H
    Cancer Med; 2020 Jan; 9(2):689-699. PubMed ID: 31758653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA ZFPM2-AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2.
    Han S; Cao D; Sha J; Zhu X; Chen D
    Mol Oncol; 2020 May; 14(5):1074-1088. PubMed ID: 31919993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRKCZ-AS1 promotes the tumorigenesis of lung adenocarcinoma via sponging miR-766-5p to modulate MAPK1.
    Wang M; Liao Q; Zou P
    Cancer Biol Ther; 2020 Apr; 21(4):364-371. PubMed ID: 31939714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
    Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
    Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA GATA6-AS1 upregulates GATA6 to regulate the biological behaviors of lung adenocarcinoma cells.
    Kang H; Ma D; Zhang J; Zhao J; Yang M
    BMC Pulm Med; 2021 May; 21(1):166. PubMed ID: 33992085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA MAFG-AS1 boosts the proliferation of lung adenocarcinoma cells via regulating miR-744-5p/MAFG axis.
    Sui Y; Lin G; Zheng Y; Huang W
    Eur J Pharmacol; 2019 Sep; 859():172465. PubMed ID: 31211984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling.
    Zhao M; Xin XF; Zhang JY; Dai W; Lv TF; Song Y
    Cancer Med; 2020 Feb; 9(3):1196-1208. PubMed ID: 31860169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p/ KLF12 axis.
    Liu Y; Liang L; Ji L; Zhang F; Chen D; Duan S; Shen H; Liang Y; Chen Y
    Aging (Albany NY); 2021 Oct; 13(19):23376-23392. PubMed ID: 34644678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.